Skip to content

Study · Observational study · n = 70,672 · 2026

14 results

Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults.

Katsura M, Horiuchi Y, Tanabe K, Wettersten N

Diabetes, obesity & metabolism27 Mar 2026Cited by 1 (Europe PMC)

PMID41891334 (opens in a new tab)DOI10.1111/dom.70721 (opens in a new tab)PepBankPUB-41891334
Publisher pagePubMedAsk about this study
Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults without diabetes treated for obesity, tirzepatide was associated with a lower incidence of major cardiovascular events than semaglutide (1.90% vs 2.18%).

    In plain wordsIn adults with obesity and no diabetes, tirzepatide was linked to fewer major heart and circulation events than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseComposite of death, acute coronary syndrome, stroke or new-onset HF at 12 months
    Study

    n = 70,672

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.86 ratio
    tirzepatide vs semaglutide
    Incidence
    1.9%
    tirzepatide

    Source sentences

    Summary
    Tirzepatide was associated with a lower incidence of the composite outcome compared with semaglutide (1.90% vs. 2.18%; hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.77-0.97; p = 0.01)
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  2. 02HumanObservational studyEfficacy outcome

    In adults without diabetes treated for obesity, semaglutide was associated with a higher incidence of major cardiovascular events than tirzepatide (2.18% vs 1.90%).

    In plain wordsIn adults with obesity and no diabetes, semaglutide was linked to more major heart and circulation events than tirzepatide.

    Peptide
    Semaglutide
    Outcome
    IncreaseComposite of death, acute coronary syndrome, stroke or new-onset HF at 12 months
    Study

    n = 70,672

    Comparator
    Tirzepatide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Incidence
    2.18%
    semaglutide

    Source sentences

    Summary
    Tirzepatide was associated with a lower incidence of the composite outcome compared with semaglutide (1.90% vs. 2.18%; hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.77-0.97; p = 0.01)
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  3. 03HumanObservational studyEfficacy outcome

    In adults without diabetes treated for obesity, tirzepatide was associated with a lower incidence of new-onset heart failure than semaglutide (1.04% vs 1.29%).

    In plain wordsIn adults with obesity and no diabetes, tirzepatide was linked to fewer new cases of heart failure than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseNew-onset heart failure
    Study

    n = 70,672

    Comparator
    Semaglutide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.79 ratio
    tirzepatide vs semaglutide
    Incidence
    1.04%
    tirzepatide

    Source sentences

    Summary
    driven by reduced new-onset HF (1.04% vs. 1.29%; HR, 0.79; 95% CI, 0.68-0.92; p = 0.002)
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  4. 04HumanObservational studyEfficacy outcome

    In adults without diabetes treated for obesity, semaglutide was associated with a higher incidence of new-onset heart failure than tirzepatide (1.29% vs 1.04%).

    In plain wordsIn adults with obesity and no diabetes, semaglutide was linked to more new cases of heart failure than tirzepatide.

    Peptide
    Semaglutide
    Outcome
    IncreaseNew-onset heart failure
    Study

    n = 70,672

    Comparator
    Tirzepatide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Incidence
    1.29%
    semaglutide

    Source sentences

    Summary
    driven by reduced new-onset HF (1.04% vs. 1.29%; HR, 0.79; 95% CI, 0.68-0.92; p = 0.002)
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  5. 05HumanObservational studyEfficacy outcome

    In adults without diabetes treated for obesity, all-cause mortality did not differ significantly between tirzepatide and semaglutide.

    In plain wordsIn adults with obesity and no diabetes, tirzepatide and semaglutide did not differ significantly in deaths from any cause.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAll-cause mortality
    Study

    n = 70,672

    Comparator
    Semaglutide
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant differences were observed in all-cause mortality, acute coronary syndrome, or stroke.
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  6. 06HumanObservational studyEfficacy outcome

    In adults without diabetes treated for obesity, all-cause mortality did not differ significantly between semaglutide and tirzepatide.

    In plain wordsIn adults with obesity and no diabetes, semaglutide and tirzepatide did not differ significantly in deaths from any cause.

    Peptide
    Semaglutide
    Outcome
    No significant changeAll-cause mortality
    Study

    n = 70,672

    Comparator
    Tirzepatide
    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant differences were observed in all-cause mortality, acute coronary syndrome, or stroke.
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  7. 07HumanObservational studyEfficacy outcome

    In adults without diabetes treated for obesity, acute coronary syndrome did not differ significantly between tirzepatide and semaglutide.

    In plain wordsIn adults with obesity and no diabetes, tirzepatide and semaglutide did not differ significantly in acute coronary syndrome.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAcute coronary syndrome
    Study

    n = 70,672

    Comparator
    Semaglutide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant differences were observed in all-cause mortality, acute coronary syndrome, or stroke.
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  8. 08HumanObservational studyEfficacy outcome

    In adults without diabetes treated for obesity, acute coronary syndrome did not differ significantly between semaglutide and tirzepatide.

    In plain wordsIn adults with obesity and no diabetes, semaglutide and tirzepatide did not differ significantly in acute coronary syndrome.

    Peptide
    Semaglutide
    Outcome
    No significant changeAcute coronary syndrome
    Study

    n = 70,672

    Comparator
    Tirzepatide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant differences were observed in all-cause mortality, acute coronary syndrome, or stroke.
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  9. 09HumanObservational studyEfficacy outcome

    In adults without diabetes treated for obesity, stroke did not differ significantly between tirzepatide and semaglutide.

    In plain wordsIn adults with obesity and no diabetes, tirzepatide and semaglutide did not differ significantly in stroke.

    Peptide
    Tirzepatide
    Outcome
    No significant changeStroke
    Study

    n = 70,672

    Comparator
    Semaglutide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant differences were observed in all-cause mortality, acute coronary syndrome, or stroke.
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  10. 10HumanObservational studyEfficacy outcome

    In adults without diabetes treated for obesity, stroke did not differ significantly between semaglutide and tirzepatide.

    In plain wordsIn adults with obesity and no diabetes, semaglutide and tirzepatide did not differ significantly in stroke.

    Peptide
    Semaglutide
    Outcome
    No significant changeStroke
    Study

    n = 70,672

    Comparator
    Tirzepatide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant differences were observed in all-cause mortality, acute coronary syndrome, or stroke.
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  11. 11HumanObservational studyEfficacy outcome

    In adults without diabetes treated for obesity, mean weight loss was greater with tirzepatide than with semaglutide (-9.8 kg vs -8.0 kg).

    In plain wordsIn adults with obesity and no diabetes, people on tirzepatide lost more weight on average than people on semaglutide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMean weight loss
    Study

    n = 70,672

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean weight change
    −9.8 kg
    tirzepatide

    Source sentences

    Summary
    Mean weight loss was greater with tirzepatide (-9.8 kg vs. -8.0 kg; p < 0.001).
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  12. 12HumanObservational studyEfficacy outcome

    In adults without diabetes treated for obesity, mean weight loss was smaller with semaglutide than with tirzepatide (-8.0 kg vs -9.8 kg).

    In plain wordsIn adults with obesity and no diabetes, people on semaglutide lost less weight on average than people on tirzepatide.

    Peptide
    Semaglutide
    Outcome
    DecreaseMean weight loss
    Study

    n = 70,672

    Comparator
    Tirzepatide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean weight change
    −8 kg
    semaglutide

    Source sentences

    Summary
    Mean weight loss was greater with tirzepatide (-9.8 kg vs. -8.0 kg; p < 0.001).
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  13. 13HumanObservational studySafety outcome

    In adults without diabetes treated for obesity, adverse event rates were comparable between tirzepatide and semaglutide, with no new safety signals.

    In plain wordsIn adults with obesity and no diabetes, tirzepatide and semaglutide had comparable side effect rates, with no new safety signals.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAdverse event rates
    Study

    n = 70,672

    Comparator
    Semaglutide
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Adverse event rates were comparable, with no new safety signals.
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.
  14. 14HumanObservational studySafety outcome

    In adults without diabetes treated for obesity, adverse event rates were comparable between semaglutide and tirzepatide, with no new safety signals.

    In plain wordsIn adults with obesity and no diabetes, semaglutide and tirzepatide had comparable side effect rates, with no new safety signals.

    Peptide
    Semaglutide
    Outcome
    No significant changeAdverse event rates
    Study

    n = 70,672

    Comparator
    Tirzepatide
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Adverse event rates were comparable, with no new safety signals.
    1 context sentence
    Summary · context
    Adults (≥ 18 years) without diabetes who initiated tirzepatide or semaglutide for the treatment of obesity between November 2023 and August 2024 were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.